Exosome technologies

Exosome therapy is a relatively new concept, with  both challenges and significant opportunities

Why Exosomes?

Exosomes are nanosized vesicles (50-200nm) released naturally by cells. They are important effectors of cell communication. A key mechanism by which cell therapies work is via release and uptake of exosomes.

Some of the properties of exosomes are:

  • they contain unique mix of molecular cargo (including miRNA, proteins, peptides, lipids) that underpin
  • their biological effect
  • they have homing capabilities that allow them to travel to the site of injury or disease
  • their immunomodulatory properties helps normalise the immune system
  • being low/non-immunogenic
  • they are not rejected by the bodythey have other bioactive properties based on parent cell e.g. angiogenesis, anti-fibrotic, regenerative, etc.

A: Cell

B: Exosome

VivaZome = Nature + Technology

VivaZome is leveraging the best that nature and technology has to offer:

Customised Exosomes
  • Cell Source is key; exploit unique cell attributes.
  • Multiple cells types screened based on their native biological function.
  • Exosome quantity and quality assessed.
  • Cell engineering and exosome loading and targeting technologies to enhance function.
  • Cell Engineering for immortalisation.
Universal Manufacturing Process
  • Optimised, best-in-class technology.
  • Proprietary components to complement established technology from leading suppliers.
  • Proprietary cells for manufacture.
  • Underpinned by extensive characterisation, molecular cargo analysis, potency assays that link attributes to function and clinical targets.

Exosomes as a therapeutic opportunity

Exosome therapy is a relatively new concept, with  both challenges and significant opportunities.

VivaZome’s focus:
Novel, scalable processes and technology

Special challenges with large- scale separation and concentration technology and analytics


No registered exosome therapies

Limited but growing clinical experience with exosomes


Evolving exosome-specific guidance from regulatory agencies

Growing number of industry players

Sophisticated exosome analytic technology for product specification

Clinical Targets

Retinal Disease Program

  • Age-related Macular Degeneration (AMD)

AMD is the leading cause of blindness in the Western World, affecting 18 million Americans, projected to reach 288 million people world-wide by 2040.

Neurological Disease Program

  • Traumatic Brain Injury (TBI)
  • Post-Traumatic Epilepsy (PTE)
  • Degenerative Brain disorders

5.3 million Americans are living with Traumatic Brain Injury at a cost of USD 76.5 billion per annum.

Ischemic Disease Program

  • Critical limb ischemia
  • Cardiac ischemia
  • Cerebral ischemia

Treatment for Critical Limb Ischemia costs >USD 10 billion per annum in USA alone.